Cargando…

What do we know about managing Dupuytren’s disease cost-effectively?

BACKGROUND: Dupuytren’s disease (DD) is a common and progressive, fibroproliferative disorder of the palmar and digital fascia of the hand. Various treatments have been recommended for advanced disease or to retard progression of early disease and to prevent deterioration of the finger contracture a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dritsaki, Melina, Rivero-Arias, Oliver, Gray, Alastair, Ball, Catherine, Nanchahal, Jagdeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785840/
https://www.ncbi.nlm.nih.gov/pubmed/29370792
http://dx.doi.org/10.1186/s12891-018-1949-2
_version_ 1783295683191635968
author Dritsaki, Melina
Rivero-Arias, Oliver
Gray, Alastair
Ball, Catherine
Nanchahal, Jagdeep
author_facet Dritsaki, Melina
Rivero-Arias, Oliver
Gray, Alastair
Ball, Catherine
Nanchahal, Jagdeep
author_sort Dritsaki, Melina
collection PubMed
description BACKGROUND: Dupuytren’s disease (DD) is a common and progressive, fibroproliferative disorder of the palmar and digital fascia of the hand. Various treatments have been recommended for advanced disease or to retard progression of early disease and to prevent deterioration of the finger contracture and quality of life. Recent studies have tried to evaluate the clinical and cost-effectiveness of therapies for DD, but there is currently no systematic assessment and appraisal of the economic evaluations. METHODS: A systematic literature review was conducted, following PRISMA guidelines, to identify studies reporting economic evaluations of interventions for managing DD. Databases searched included the Ovid MEDLINE/Embase (without time restriction), National Health Service (NHS) Economic Evaluation Database (all years) and the National Institute for Health Research (NIHR) Journals Library) Health Technology Assessment (HTA). Cost-effectiveness analyses of treating DD were identified and their quality was assessed using the CHEERS assessment tool for quality of reporting and Phillips checklist for model evaluation. RESULTS: A total of 103 studies were screened, of which 4 met the study inclusion criteria. Two studies were from the US, one from the UK and one from Canada. They all assessed the same interventions for advanced DD, namely collagenase Clostridium histolyticum injection, percutaneous needle fasciotomy and partial fasciectomy. All studies conducting a cost-utility analysis, two implemented a decision analytic model and two a Markov model approach. None of them were based on a single randomised controlled trial, but rather synthesised evidence from various sources. Studies varied in their time horizon, sources of utility estimates and perspective of analysis. The overall quality of study reporting was good based on the CHEERS checklist. The quality of the model reporting in terms of model structure, data synthesis and model consistency varied across the included studies. CONCLUSION: Cost-effectiveness analyses for patients with advanced DD are limited and have applied different approaches with respect to modelling. Future studies should improve the way they are conducted and report their findings according to established guidance for conducting economic modelling of health care technologies. TRIAL REGISTRATION: The protocol was registered (CRD42016032989; date 08/01/2016) with the PROSPERO international prospective register of systematic reviews. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12891-018-1949-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5785840
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57858402018-02-07 What do we know about managing Dupuytren’s disease cost-effectively? Dritsaki, Melina Rivero-Arias, Oliver Gray, Alastair Ball, Catherine Nanchahal, Jagdeep BMC Musculoskelet Disord Research Article BACKGROUND: Dupuytren’s disease (DD) is a common and progressive, fibroproliferative disorder of the palmar and digital fascia of the hand. Various treatments have been recommended for advanced disease or to retard progression of early disease and to prevent deterioration of the finger contracture and quality of life. Recent studies have tried to evaluate the clinical and cost-effectiveness of therapies for DD, but there is currently no systematic assessment and appraisal of the economic evaluations. METHODS: A systematic literature review was conducted, following PRISMA guidelines, to identify studies reporting economic evaluations of interventions for managing DD. Databases searched included the Ovid MEDLINE/Embase (without time restriction), National Health Service (NHS) Economic Evaluation Database (all years) and the National Institute for Health Research (NIHR) Journals Library) Health Technology Assessment (HTA). Cost-effectiveness analyses of treating DD were identified and their quality was assessed using the CHEERS assessment tool for quality of reporting and Phillips checklist for model evaluation. RESULTS: A total of 103 studies were screened, of which 4 met the study inclusion criteria. Two studies were from the US, one from the UK and one from Canada. They all assessed the same interventions for advanced DD, namely collagenase Clostridium histolyticum injection, percutaneous needle fasciotomy and partial fasciectomy. All studies conducting a cost-utility analysis, two implemented a decision analytic model and two a Markov model approach. None of them were based on a single randomised controlled trial, but rather synthesised evidence from various sources. Studies varied in their time horizon, sources of utility estimates and perspective of analysis. The overall quality of study reporting was good based on the CHEERS checklist. The quality of the model reporting in terms of model structure, data synthesis and model consistency varied across the included studies. CONCLUSION: Cost-effectiveness analyses for patients with advanced DD are limited and have applied different approaches with respect to modelling. Future studies should improve the way they are conducted and report their findings according to established guidance for conducting economic modelling of health care technologies. TRIAL REGISTRATION: The protocol was registered (CRD42016032989; date 08/01/2016) with the PROSPERO international prospective register of systematic reviews. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12891-018-1949-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-25 /pmc/articles/PMC5785840/ /pubmed/29370792 http://dx.doi.org/10.1186/s12891-018-1949-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Dritsaki, Melina
Rivero-Arias, Oliver
Gray, Alastair
Ball, Catherine
Nanchahal, Jagdeep
What do we know about managing Dupuytren’s disease cost-effectively?
title What do we know about managing Dupuytren’s disease cost-effectively?
title_full What do we know about managing Dupuytren’s disease cost-effectively?
title_fullStr What do we know about managing Dupuytren’s disease cost-effectively?
title_full_unstemmed What do we know about managing Dupuytren’s disease cost-effectively?
title_short What do we know about managing Dupuytren’s disease cost-effectively?
title_sort what do we know about managing dupuytren’s disease cost-effectively?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785840/
https://www.ncbi.nlm.nih.gov/pubmed/29370792
http://dx.doi.org/10.1186/s12891-018-1949-2
work_keys_str_mv AT dritsakimelina whatdoweknowaboutmanagingdupuytrensdiseasecosteffectively
AT riveroariasoliver whatdoweknowaboutmanagingdupuytrensdiseasecosteffectively
AT grayalastair whatdoweknowaboutmanagingdupuytrensdiseasecosteffectively
AT ballcatherine whatdoweknowaboutmanagingdupuytrensdiseasecosteffectively
AT nanchahaljagdeep whatdoweknowaboutmanagingdupuytrensdiseasecosteffectively